Search

Your search keyword '"Heidt S"' showing total 347 results
Start Over Author "Heidt S"
347 results on '"Heidt S"'

10. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program

Author

Fijter, J. de, Dreyer, G., Mallat, M., Budde, K., Pratschke, J., Klempnauer, J., Zeier, M., Arns, W., Hugo, C., Rump, L.C., Hauser, I., Schenker, P., Schiffer, M., Grimm, M.O., Kliem, V., Olbricht, C.J., Pisarski, P., Banas, B., Suwelack, B., Hakenberg, O., Berlakovich, G., Schneeberger, S., Wetering, J. van de, Berger, S., Bemelman, F., Kuypers, D., Heidt, S., Rahmel, A., Claas, F., Peeters, P., Oberbauer, R., Hilbrands, L.B., Heemann, U., Krämer, B.K., Fijter, J. de, Dreyer, G., Mallat, M., Budde, K., Pratschke, J., Klempnauer, J., Zeier, M., Arns, W., Hugo, C., Rump, L.C., Hauser, I., Schenker, P., Schiffer, M., Grimm, M.O., Kliem, V., Olbricht, C.J., Pisarski, P., Banas, B., Suwelack, B., Hakenberg, O., Berlakovich, G., Schneeberger, S., Wetering, J. van de, Berger, S., Bemelman, F., Kuypers, D., Heidt, S., Rahmel, A., Claas, F., Peeters, P., Oberbauer, R., Hilbrands, L.B., Heemann, U., and Krämer, B.K.

Abstract

Item does not contain fulltext, The Eurotransplant Senior Program (ESP) has expedited the chance for elderly patients with kidney failure to receive a timely transplant. This current study evaluated survival parameters of kidneys donated after brain death with or without matching for HLA-DR antigens. This cohort study evaluated the period within ESP with paired allocation of 675 kidneys from donors 65 years and older to transplant candidates 65 years and older, the first kidney to 341 patients within the Eurotransplant Senior DR-compatible Program and 334 contralateral kidneys without (ESP) HLA-DR antigen matching. We used Kaplan-Meier estimates and competing risk analysis to assess all cause mortality and kidney graft failure, respectively. The log-rank test and Cox proportional hazards regression were used for comparisons. Within ESP, matching for HLA-DR antigens was associated with a significantly lower five-year risk of mortality (hazard ratio 0.71; 95% confidence interval 0.53-0.95) and significantly lower cause-specific hazards for kidney graft failure and return to dialysis at one year (0.55; 0.35-0.87) and five years (0.73; 0.53-0.99) post-transplant. Allocation based on HLA-DR matching resulted in longer cold ischemia (mean difference 1.00 hours; 95% confidence interval: 0.32-1.68) and kidney offers with a significantly shorter median dialysis vintage of 2.4 versus 4.1 yrs. in ESP without matching. Thus, our allocation based on HLA-DR matching improved five-year patient and kidney allograft survival. Hence, our paired allocation study suggests a superior outcome of HLA-DR matching in the context of old-for-old kidney transplantation.

Published
2023

11. Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC

Author

Dreyer, GJ, Drabbels, JJM, de Fijter, JW, van Kooten, C, Reinders, MEJ, Heidt, S, Dreyer, GJ, Drabbels, JJM, de Fijter, JW, van Kooten, C, Reinders, MEJ, and Heidt, S

Abstract

Introduction: Mesenchymal stromal cell (MSC) therapy is a promising treatment that allows for drug minimization in clinical kidney transplantation. While it is thought that MSCs rapidly go into apoptosis after infusion, clinical evidence for this is scarce since methods to detect cell death of infused cells in vivo are lacking. Cell-free DNA (cfDNA) has recently gained attention as a biomarker for cell death. Methods: In this study, we longitudinally measured cfDNA in plasma samples of the recipient, kidney donor, and allogeneic third-party MSC in the context of the Neptune study. cfDNA levels were measured at several time points before and after allogeneic MSC infusion in the 10 recipients who participated in the Neptune study. cfDNA ratios between the recipient, kidney graft, and MSC were determined. Results: We observed a peak in MSC-derived cfDNA 4 h after the first and second infusions, after which MSC-derived cfDNA became undetectable. Generally, kidney graft-derived cfDNA remained in the baseline-level range. Discussion: Our results support preclinical data that MSC are short-lived after infusion, also in a clinical in vivo setting, and are relevant for further research into the mechanism of action of MSC therapy.

Published
2023

12. Immunologic risk stratification of pediatric heart transplant patients by combining HLA-EMMA and PIRCHE-II

Author

Ellison, M., Mangiola, M., Marrari, M., Bentlejewski, C., Sadowski, J., Zern, D., Kramer, Cynthia Silvia Maria, Heidt, S., Niemann, M., Xu, Q., Dipchand, A. I., Mahle, W. T., Rossano, J. W., Canter, C. E., Singh, T. P., Zuckerman, W. A., Hsu, D. T., Feingold, B., Webber, S. A., Zeevi, A., Ellison, M., Mangiola, M., Marrari, M., Bentlejewski, C., Sadowski, J., Zern, D., Kramer, Cynthia Silvia Maria, Heidt, S., Niemann, M., Xu, Q., Dipchand, A. I., Mahle, W. T., Rossano, J. W., Canter, C. E., Singh, T. P., Zuckerman, W. A., Hsu, D. T., Feingold, B., Webber, S. A., and Zeevi, A.

Abstract

Human leukocyte antigen (HLA) molecular mismatch is a powerful biomarker of rejection. Few studies have explored its use in assessing rejection risk in heart transplant recipients. We tested the hypothesis that a combination of HLA Epitope Mismatch Algorithm (HLA-EMMA) and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE-II) algorithms can improve risk stratification of pediatric heart transplant recipients. Class I and II HLA genotyping were performed by next-generation sequencing on 274 recipient/donor pairs enrolled in the Clinical Trials in Organ Transplantation in Children (CTOTC). Using high-resolution genotypes, we performed HLA molecular mismatch analysis with HLA-EMMA and PIRCHE-II, and correlated these findings with clinical outcomes. Patients without pre-formed donor specific antibody (DSA) (n=100) were used for correlations with post-transplant DSA and antibody mediated rejection (ABMR). Risk cut-offs were determined for DSA and ABMR using both algorithms. HLA-EMMA cut-offs alone predict the risk of DSA and ABMR; however, if used in combination with PIRCHE-II, the population could be further stratified into low-, intermediate-, and high-risk groups. The combination of HLA-EMMA and PIRCHE-II enables more granular immunological risk stratification. Intermediate-risk cases, like low-risk cases, are at a lower risk of DSA and ABMR. This new way of risk evaluation may facilitate individualized immunosuppression and surveillance.

Published
2023

13. Evaluation of 19years of international external proficiency testing for high-resolution HLA typing.

Author

Voorter, C. E. M., Groeneveld, L., Heidt, S., and Wieten, L.

Subjects
EUROPEAN integration, IMMUNOGENETICS, TESTING laboratories, ALLELES, LEUCOCYTES, TANDEM repeats
Abstract

The international high-resolution external proficiency testing (EPT) started in 2004 with high-resolution typing of human leucocyte antigen (HLA) class I (HLA-A,B,C) and HLA class II (HLA-DRB1, DRB345, DQB1, and DPB1) alleles, since possibilities for such an EPT within Europe were limited and all existing EPTs at that time made use of the comparison of HLA typing results without a reference. This EPT was set up as a collaboration between the HLA laboratory of Leiden, providing DNA samples to the participants, and the laboratory of Maastricht, performing the high-resolution typing as the reference result and evaluating the results of all participants according to the prevailing European Federation for Immunogenetics (EFI) standards. Once a year, 12 samples were sent to the participating laboratories, and evaluation and certificates were provided at the end of that same year. During the years, the EPT was extended to lowresolution HLA class I and II typing, high-resolution typing including DQA1 and DPA1, and allelic resolution typing for HLA class I, the latter one being unique in this field. Evaluation of the high-resolution typing results of the last 19 years showed a clear increase in the number of loci tested by the participating laboratories and a clear change of method from Sanger sequencing with additional other techniques (SSO/SSP) to the nowadays widely used nextgeneration sequencing method. By strictly using the EFI rules for highresolution HLA typing, the participants were made aware of the ambiguities within exons 2 and 3 for class I and exon 2 for class II and the presence of null alleles even in a two-field HLA typing. There was an impressive learning curve, resulting in >98% correctly typed samples since 2017 and a 100% fulfillment of EFI rules for all laboratories for all loci submitted in the last 2 years. Overall, this EPT meets the need of an EPT for high-resolution typing for EFI accreditation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. O010 A novel microfluidic immunoassay for in-solution quantification of alloantibody affinity and concentration in transplantation and beyond

Author

Priddey, A, primary, Karahan, G, additional, Schneider, M, additional, Meisl, G, additional, Scheidt, T, additional, Xu, C, additional, Peacock, S, additional, Buchli, R, additional, Mulder, A, additional, Heidt, S, additional, Class, F, additional, Knowles, T, additional, and Kosmolipaptsis, V, additional

Published
2023
Full Text
View/download PDF

15. Immunologic risk stratification of pediatric heart transplant patients by combining HLA-EMMA and PIRCHE-II

Author

Ellison, M., primary, Mangiola, M., additional, Marrari, M., additional, Bentlejewski, C., additional, Sadowski, J., additional, Zern, D., additional, Kramer, Cynthia Silvia Maria, additional, Heidt, S., additional, Niemann, M., additional, Xu, Q., additional, Dipchand, A. I., additional, Mahle, W. T., additional, Rossano, J. W., additional, Canter, C. E., additional, Singh, T. P., additional, Zuckerman, W. A., additional, Hsu, D. T., additional, Feingold, B., additional, Webber, S. A., additional, and Zeevi, A., additional

Published
2023
Full Text
View/download PDF

16. Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids

Author

Gaykema, L.H., Nieuwland, R.Y. van, Dekkers, M.C., Essen, M.F. van, Heidt, S., Zaldumbide, A., Berg, C.W. van den, Rabelink, T.J., and Kooten, C. van

Subjects
immune modulation, Immunology, Immunology and Allergy, iPSCs, complement, CD55 (DAF), kidney organoids, CRISPR-Cas9, transplantation
Abstract

End stage renal disease is an increasing problem worldwide driven by aging of the population and increased prevalence of metabolic disorders and cardiovascular disease. Currently, kidney transplantation is the only curative option, but donor organ shortages greatly limit its application. Regenerative medicine has the potential to solve the shortage by using stem cells to grow the desired tissues, like kidney tissue. Immune rejection poses a great threat towards the implementation of stem cell derived tissues and various strategies have been explored to limit the immune response towards these tissues. However, these studies are limited by targeting mainly T cell mediated immune rejection while the rejection process also involves innate and humoral immunity. In this study we investigate whether inhibition of the complement system in human induced pluripotent stem cells (iPSC) could provide protection from such immune injury. To this end we created knock-in iPSC lines of the membrane bound complement inhibitor CD55 to create a transplant-specific protection towards complement activation. CD55 inhibits the central driver of the complement cascade, C3 convertase, and we show that overexpression is able to decrease complement activation on both iPSCs as well as differentiated kidney organoids upon stimulation with anti-HLA antibodies to mimic the mechanism of humoral rejection.

Published
2023

17. Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets

Author

Van Osch, TLJ, Oosterhoff, JJ, Bentlage, AEH, Nouta, J, Koeleman, CAM, Geerdes, DM, Mok, JY, Heidt, S, Mulder, A, Van, Esch WJE, Kapur, R, Porcelijn, L, Vidarsson, G, Afd Biomol.Mass Spect. and Proteomics, and Biomolecular Mass Spectrometry and Proteomics

Abstract

Approximately 20% of patients receiving multiple platelet transfusions develop platelet alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a lesser extent, against human platelet antigens (HPA). These antibodies can lead to the rapid clearance of donor platelets, presumably through IgG-Fc receptor (FcγR)-mediated phagocytosis or via complement activation, resulting in platelet refractoriness. Strikingly, not all patients with anti-HLA or -HPA antibodies develop platelet refractoriness upon unmatched platelet transfusions. Previously, we found that IgG Fc glycosylation of anti-HLA antibodies was highly variable between patients with platelet refractoriness, especially with respect to galactosylation and sialylation of the Fc-bound sugar moiety. Here, we produced recombinant glycoengineered anti-HLA and anti- HPA-1a monoclonal antibodies with varying Fc galactosylation and sialylation levels and studied their ability to activate the classical complement pathway. We observed that anti-HLA monoclonal antibodies with different specificities, binding simultaneously to the same HLA-molecules, or anti-HLA in combination with anti-HPA-1a monoclonal antibodies interacted synergistically with C1q, the first component of the classical pathway. Elevated Fc galactosylation and, to a lesser extent, sialylation significantly increased the complement-activating properties of anti-HLA and anti-HPA-1a monoclonal antibodies. We propose that both the breadth of the polyclonal immune response, with recognition of different HLA epitopes and in some cases HPA antigens, and the type of Fc glycosylation can provide an optimal stoichiometry for C1q binding and subsequent complement activation. These factors can shift the effect of a platelet alloimmune response to a clinically relevant response, leading to complement-mediated clearance of donor platelets, as observed in platelet refractoriness.

Published
2022

18. Imaging mass cytometry reveals the prominent role of myeloid cells at the maternal-fetal interface

Author

Krop, J., Zwan, A. van der, Ijsselsteijn, M.E., Kapsenberg, H., Luk, S.J., Hendriks, S.H., Keur, C. van der, Verleng, L.J., Somarakis, A., Meeren, L. van der, Haasnoot, G., Bos, M., Miranda, N.F.C.C. de, Lopes, S.M.C.D., Hoorn, M.L.P. van der, Koning, F., Claas, F.H.J., Heidt, S., Eikmans, M., and Pathology

Subjects
Multidisciplinary, SDG 3 - Good Health and Well-being
Abstract

Although the immunological complexity of the maternal-fetal interface is well appreciated, the actual interaction of maternal immune cells and fetal trophoblasts is insufficiently understood. To comprehend the composition and spatial orientation of maternal immune cells and fetal extravillous trophoblasts, we applied imaging mass cytometry on decidua basalis of the three trimesters of healthy pregnancy. Within all trimesters, we observed considerably higher frequencies of myeloid cells in the decidua than is seen with single-cell suspension techniques. Moreover, they were the most pronounced cell type in the microenvironment of other decidual cells. In first trimester, HLA-DR- macrophages represented the most abundant myeloid subcluster and these cells were frequently observed in the vicinity of trophoblasts. At term, HLA-DR+ macrophage subclusters were abundantly present and frequently observed in the microenvironment of T cells. Taken together, our results highlight the dynamic role of myeloid cells at the human maternal-fetal interface throughout gestation.

Published
2022

21. Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets

Author

Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Van Osch, TLJ, Oosterhoff, JJ, Bentlage, AEH, Nouta, J, Koeleman, CAM, Geerdes, DM, Mok, JY, Heidt, S, Mulder, A, Van, Esch WJE, Kapur, R, Porcelijn, L, Vidarsson, G, Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Van Osch, TLJ, Oosterhoff, JJ, Bentlage, AEH, Nouta, J, Koeleman, CAM, Geerdes, DM, Mok, JY, Heidt, S, Mulder, A, Van, Esch WJE, Kapur, R, Porcelijn, L, and Vidarsson, G

Published
2022

22. Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets

Author

Osch, T.L.J. van, Oosterhoff, J.J., Bentlage, A.E.H., Nouta, J., Koeleman, C.A.M., Geerdes, D.M., Mok, J.Y., Heidt, S., Mulder, A., Esch, W.J.E. van, Kapur, R., Porcelijn, L., Schoot, E.V., Haas, M. de, Wuhrer, M., Voorberg, J., Vidarsson, G., Graduate School, Landsteiner Laboratory, Clinical Haematology, AII - Inflammatory diseases, Experimental Vascular Medicine, and ACS - Microcirculation

Subjects
Blood Platelets, Complement C1q, Receptors, IgG, Antibodies, Monoclonal, Complement System Proteins, Hematology, Thrombocytopenia, Epitopes, HLA Antigens, Isoantibodies, Immunoglobulin G, Humans, Antigens, Human Platelet, Complement Pathway, Classical, Sugars
Abstract

Approximately 20% of patients receiving multiple platelet transfusions develop platelet alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a lesser extent, against human platelet antigens (HPA). These antibodies can lead to the rapid clearance of donor platelets, presumably through IgG-Fc receptor (FcγR)-mediated phagocytosis or via complement activation, resulting in platelet refractoriness. Strikingly, not all patients with anti-HLA or -HPA antibodies develop platelet refractoriness upon unmatched platelet transfusions. Previously, we found that IgG Fc glycosylation of anti-HLA antibodies was highly variable between patients with platelet refractoriness, especially with respect to galactosylation and sialylation of the Fc-bound sugar moiety. Here, we produced recombinant glycoengineered anti-HLA and anti- HPA-1a monoclonal antibodies with varying Fc galactosylation and sialylation levels and studied their ability to activate the classical complement pathway. We observed that anti-HLA monoclonal antibodies with different specificities, binding simultaneously to the same HLA-molecules, or anti-HLA in combination with anti-HPA-1a monoclonal antibodies interacted synergistically with C1q, the first component of the classical pathway. Elevated Fc galactosylation and, to a lesser extent, sialylation significantly increased the complement-activating properties of anti-HLA and anti-HPA-1a monoclonal antibodies. We propose that both the breadth of the polyclonal immune response, with recognition of different HLA epitopes and in some cases HPA antigens, and the type of Fc glycosylation can provide an optimal stoichiometry for C1q binding and subsequent complement activation. These factors can shift the effect of a platelet alloimmune response to a clinically relevant response, leading to complement-mediated clearance of donor platelets, as observed in platelet refractoriness.

Published
2022

26. Donor-specific B cell memory in alloimmunized kidney transplant recipients: first clinical application of a novel method

Author

Wehmeier, C., Karahan, G.E., Krop, J., Vaal, Y. de, Langerak-Langerak, J., Binet, I., Schaub, S., Roelen, D.L., Claas, F.H.J., Heidt, S., and Swiss Transplant Cohort Study

Subjects
Graft Rejection, Male, medicine.medical_specialty, Biopsy, Pilot Projects, 030230 surgery, Peripheral blood mononuclear cell, Kidney transplant, Gastroenterology, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Antigen, HLA Antigens, Isoantibodies, Internal medicine, medicine, Humans, Kidney transplantation, B cell, Retrospective Studies, Transplantation, B-Lymphocytes, medicine.diagnostic_test, business.industry, Incidence (epidemiology), Histocompatibility Testing, Incidence, Retrospective cohort study, Middle Aged, medicine.disease, Kidney Transplantation, Tissue Donors, body regions, medicine.anatomical_structure, 030211 gastroenterology & hepatology, Female, business, Immunologic Memory, Switzerland, Follow-Up Studies
Abstract

Background.HLA-specific memory B cells may contribute to the serum HLA antibody pool upon antigen reexposure. The aim of this pilot study was to investigate the presence of concurrent donor-specific memory B cell-derived HLA antibodies (DSA-M) in renal allograft recipients with pretransplant donor-specific HLA antibodies (DSA) and its association with occurrence of antibody-mediated rejection (AMR) using a recently developed method.Methods.Twenty patients with Luminex single antigen bead (SAB) assay-defined DSA but negative complement-dependent cytotoxicity crossmatches were enrolled. Plasma samples and peripheral blood mononuclear cells were collected at 3 timepoints (pretransplant, mo 6, mo 12). We analyzed IgG-purified and concentrated culture supernatants from polyclonally activated peripheral blood mononuclear cells using SAB assays and compared HLA antibody profiles with same day plasma results.Results.Plasma SAB analysis revealed 35 DSA in 20 patients pretransplant. DSA-M were detected in 9 of 20 (45%) patients and for 10 of 35 specificities (29%). While median mean fluorescence intensity values of DSA with concurrent DSA-M (5877) were higher than those of DSA without DSA-M (1476), 3 of 6 patients with AMR and low mean fluorescence intensity DSA (= 1 + ptc >= 1) of microvascular inflammation (67% vs 9%, P = 0.02). In 17 patients (28 DSA) with posttransplant analyses, persisting DSA posttransplant had more often DSA-M (6/12; 50%) than nonpersisting DSA (2/16; 13%).Conclusions.Assessment of DSA-M might be a novel tool to supplement serum HLA antibody analysis for pretransplant risk stratification in patients with DSA.

Published
2020

29. T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation

Author

Peereboom, E.T.M., Matern, B.M., Tomosugi, T., Niemann, M., Drylewicz, J., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Reekum, F.E. van, Verhaar, M.C., Kamburova, E.G., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, Karlijn A.M.I. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Vries, A.P.J de, Fijter, J.W. de, Betjes, M. G. H., Roelen, D.L., Claas, F.H.J., Otten, H.G., Heidt, S., Zuilen, A.D. van, Kobayashi, T., Geneugelijk, K., Spierings, E, Peereboom, E.T.M., Matern, B.M., Tomosugi, T., Niemann, M., Drylewicz, J., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Reekum, F.E. van, Verhaar, M.C., Kamburova, E.G., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, Karlijn A.M.I. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Vries, A.P.J de, Fijter, J.W. de, Betjes, M. G. H., Roelen, D.L., Claas, F.H.J., Otten, H.G., Heidt, S., Zuilen, A.D. van, Kobayashi, T., Geneugelijk, K., and Spierings, E

Abstract

Contains fulltext : 241482.pdf (Publisher’s version ) (Open Access), CD4(+) T-helper cells play an important role in alloimmune reactions following transplantation by stimulating humoral as well as cellular responses, which might lead to failure of the allograft. CD4(+) memory T-helper cells from a previous immunizing event can potentially be reactivated by exposure to HLA mismatches that share T-cell epitopes with the initial immunizing HLA. Consequently, reactivity of CD4(+) memory T-helper cells toward T-cell epitopes that are shared between immunizing HLA and donor HLA could increase the risk of alloimmunity following transplantation, thus affecting transplant outcome. In this study, the amount of T-cell epitopes shared between immunizing and donor HLA was used as a surrogate marker to evaluate the effect of donor-reactive CD4(+) memory T-helper cells on the 10-year risk of death-censored kidney graft failure in 190 donor/recipient combinations using the PIRCHE-II algorithm. The T-cell epitopes of the initial theoretical immunizing HLA and the donor HLA were estimated and the number of shared PIRCHE-II epitopes was calculated. We show that the natural logarithm-transformed PIRCHE-II overlap score, or Shared T-cell EPitopes (STEP) score, significantly associates with the 10-year risk of death-censored kidney graft failure, suggesting that the presence of pre-transplant donor-reactive CD4(+) memory T-helper cells might be a strong indicator for the risk of graft failure following kidney transplantation.

Published
2021

30. A Combined microRNA and Chemokine Profile in Urine to Identify Rejection After Kidney Transplantation

Author

Gielis, E.M., Anholts, J.D.H., Beelen, E. van, Haasnoot, G.W., Fijter, H.W. De, Bajema, I., Heidt, S., Vrie, M. van de, Hilbrands, L.B., Mallat, M.J., Ledeganck, K.J., Claas, F.H.J., Eikmans, M., Gielis, E.M., Anholts, J.D.H., Beelen, E. van, Haasnoot, G.W., Fijter, H.W. De, Bajema, I., Heidt, S., Vrie, M. van de, Hilbrands, L.B., Mallat, M.J., Ledeganck, K.J., Claas, F.H.J., and Eikmans, M.

Abstract

Contains fulltext : 235565.pdf (Publisher’s version ) (Open Access), There is an unmet need for noninvasive tools for diagnosis of rejection after kidney transplantation. The aim of this study was to determine the discriminative value of a combined cellular and molecular biomarker platform in urine for the detection of rejection. METHODS: First, microRNA (miR) molecules were screened in transplant biopsies and urine sediments of patients with acute rejection and patients without rejection and stable graft function. Second, the expression of 15 selected miRs was quantified in an independent set of 115 urine sediments of patients with rejection and 55 urine sediments of patients without histological signs of rejection on protocol biopsy. Additionally, CXCL-9 and CXCL-10 protein levels were quantified in the urine supernatant. RESULTS: Levels of miR-155-5p (5.7-fold), miR-126-3p (4.2-fold), miR-21-5p (3.7-fold), miR-25-3p (2.5-fold), and miR-615-3p (0.4-fold) were significantly different between rejection and no-rejection urine sediments. CXCL-9 and CXCL-10 levels were significantly elevated in urine from recipients with rejection. In a multivariable model (sensitivity: 89.1%, specificity: 75.6%, area under the curve: 0.94, P < 0.001), miR-155-5p, miR-615-3p, and CXCL-9 levels were independent predictors of rejection. Stratified 10-fold cross validation of the model resulted in an area under the curve of 0.92. CONCLUSIONS: A combined urinary microRNA and chemokine profile discriminates kidney transplant rejection from stable graft conditions.

Published
2021

31. Improve in-depth immunological risk assessment to optimize genetic-compatibility and clinical outcomes in child and adolescent recipients of parental donor kidney transplants: protocol for the INCEPTION study

Author

Lim, WH, Adams, B, Alexander, S, Bouts, AHM, Claas, F, Collins, M, Cornelissen, E, Dunckley, H, de Jong, H, D'Orsogna, L, Francis, A, Heidt, S, Herman, J, Holdsworth, R, Kausman, J, Khalid, R, Kim, JJ, Kim, S, Knops, N, Kosmoliaptsis, V, Kramer, C, Kuypers, D, Larkins, N, Palmer, SC, Prestidge, C, Prytula, A, Sharma, A, Shingde, M, Taverniti, A, Teixeira-Pinto, A, Trnka, P, Willis, F, Wong, D, Wong, G, Lim, WH, Adams, B, Alexander, S, Bouts, AHM, Claas, F, Collins, M, Cornelissen, E, Dunckley, H, de Jong, H, D'Orsogna, L, Francis, A, Heidt, S, Herman, J, Holdsworth, R, Kausman, J, Khalid, R, Kim, JJ, Kim, S, Knops, N, Kosmoliaptsis, V, Kramer, C, Kuypers, D, Larkins, N, Palmer, SC, Prestidge, C, Prytula, A, Sharma, A, Shingde, M, Taverniti, A, Teixeira-Pinto, A, Trnka, P, Willis, F, Wong, D, and Wong, G

Abstract

BACKGROUND: Parental donor kidney transplantation is the most common treatment option for children and adolescents with kidney failure. Emerging data from observational studies have reported improved short- and medium-term allograft outcomes in recipients of paternal compared to maternal donors. The INCEPTION study aims to identify potential differences in immunological compatibility between maternal and paternal donor kidneys and ascertain how this affects kidney allograft outcomes in children and adolescents with kidney failure. METHODS: This longitudinal observational study will recruit kidney transplant recipients aged ≤18 years who have received a parental donor kidney transplant across 4 countries (Australia, New Zealand, United Kingdom and the Netherlands) between 1990 and 2020. High resolution human leukocyte antigen (HLA) typing of both recipients and corresponding parental donors will be undertaken, to provide an in-depth assessment of immunological compatibility. The primary outcome is a composite of de novo donor-specific anti-HLA antibody (DSA), biopsy-proven acute rejection or allograft loss up to 60-months post-transplantation. Secondary outcomes are de novo DSA, biopsy-proven acute rejection, acute or chronic antibody mediated rejection or Chronic Allograft Damage Index (CADI) score of > 1 on allograft biopsy post-transplant, allograft function, proteinuria and allograft loss. Using principal component analysis and Cox proportional hazards regression modelling, we will determine the associations between defined sets of immunological and clinical parameters that may identify risk stratification for the primary and secondary outcome measures among young people accepting a parental donor kidney for transplantation. This study design will allow us to specifically investigate the relative importance of accepting a maternal compared to paternal donor, for families deciding on the best option for donation. DISCUSSION: The INCEPTION study findings will explo

Published
2021

37. Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival

Author

Wisse, B.W., Kamburova, E.G., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Stephan Sanders, J., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., van Duijnhoven, E.M., Gelens, M., Christiaans, M.H., van Ittersum, F.J., Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., Wisse, B.W., Kamburova, E.G., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Stephan Sanders, J., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., van Duijnhoven, E.M., Gelens, M., Christiaans, M.H., van Ittersum, F.J., Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., and Otten, H.G.

Abstract

Contains fulltext : 204258.pdf (publisher's version ) (Open Access), BACKGROUND: There is no consensus in the literature on the interpretation of single-antigen bead positive for a specific HLA antibody. METHODS: To inform the debate, we studied the relationship between various single-antigen bead positivity algorithms and the impact of resulting donor-specific HLA antibody (DSA) positivity on long-term kidney graft survival in 3237 deceased-donor transplants. RESULTS: First, we showed that the interassay variability can be greatly reduced when working with signal-to-background ratios instead of absolute median fluorescence intensities (MFIs). Next, we determined pretransplant DSA using various MFI cutoffs, signal-to-background ratios, and combinations thereof. The impact of the various cutoffs was studied by comparing the graft survival between the DSA-positive and DSA-negative groups. We did not observe a strong impact of various cutoff levels on 10-year graft survival. A stronger relationship between the cutoff level and 1-year graft survival for DSA-positive transplants was found when using signal-to-background ratios, most pronounced for the bead of the same HLA locus with lowest MFI taken as background. CONCLUSIONS: With respect to pretransplant risk stratification, we propose a signal-to-background ratio-6 (using the bead of the same HLA-locus with lowest MFI as background) cutoff of 15 combined with an MFI cutoff of 500, resulting in 8% and 21% lower 1- and 10-year graft survivals, respectively, for 8% DSA-positive transplants.

Published
2019

38. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients

Author

Heidt, S., Haasnoot, G.W., Witvliet, M.D., Linden-van Oevelen, M.J.H. van der, Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Otten, H.G., Roelen, D.L., Claas, F.H., Heidt, S., Haasnoot, G.W., Witvliet, M.D., Linden-van Oevelen, M.J.H. van der, Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Bemelman, F.J., Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Otten, H.G., Roelen, D.L., and Claas, F.H.

Abstract

Contains fulltext : 208426.pdf (publisher's version ) (Open Access), Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the patient's HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never made antibodies, as determined by extensive laboratory testing. AM patients have superior long-term graft survival compared with highly sensitized patients in regular allocation. Here, we questioned whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected deceased donor single transplants with a minimum of 1 HLA mismatch and determined the cumulative 6-month rejection incidence for patients in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed significantly lower rejection rates than highly immunized patients in regular allocation, comparable to nonsensitized patients, independent of other risk factors for rejection. In contrast to highly sensitized patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. Allocation based on acceptable antigens leads to relatively low-risk transplants for highly sensitized patients with rejection rates similar to those of nonimmunized individuals.

Published
2019

39. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival

Author

Michielsen, L.A., Wisse, B.W., Kamburova, E.G., Verhaar, M.C., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E, Hack, C.E., Reekum, F.E. van, Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.F., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., Zuilen, A.D. van, Michielsen, L.A., Wisse, B.W., Kamburova, E.G., Verhaar, M.C., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E, Hack, C.E., Reekum, F.E. van, Bots, M.L., Drop, A., Plaisier, L., Seelen, M.A., Sanders, J.F., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J. ten, Bemelman, F.J., Hoitsma, A.J., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Otten, H.G., and Zuilen, A.D. van

Abstract

Item does not contain fulltext, BACKGROUND: Pre-transplant donor-specific anti-human leucocyte antigen (HLA) antibodies (DSAs) are associated with impaired kidney graft survival while the clinical relevance of non-donor-specific anti-HLA antibodies (nDSAs) is more controversial. The aim of the present paired kidney graft study was to compare the clinical relevance of DSAs and nDSAs. METHODS: To eliminate donor and era-dependent factors, a post hoc paired kidney graft analysis was performed as part of a Dutch multicentre study evaluating all transplantations between 1995 and 2005 with available pre-transplant serum samples. Anti-HLA antibodies were detected with a Luminex single-antigen bead assay. RESULTS: Among 3237 deceased donor transplantations, we identified 115 recipient pairs receiving a kidney from the same donor with one recipient being DSA positive and the other without anti-HLA antibodies. Patients with pre-transplant DSAs had a significantly lower 10-year death-censored graft survival (55% versus 82%, P=0.0001). We identified 192 pairs with one recipient as nDSA positive (against Class I and/or II) and the other without anti-HLA antibodies. For the patients with nDSAs against either Class I or II, graft survival did not significantly differ compared with patients without anti-HLA antibodies (74% versus 77%, P = 0.79). Only in patients with both nDSAs Class I and II was there a trend towards a lower graft survival (58%, P = 0.06). Lastly, in a small group of 42 recipient pairs, 10-year graft survival in recipients with DSAs was 49% compared with 68% in recipients with nDSAs (P=0.11). CONCLUSION: This paired kidney analysis confirms that the presence of pre-transplant DSAs in deceased donor transplantations is a risk marker for graft loss, whereas nDSAs in general are not associated with a lower graft survival. Subgroup analysis indicated that only in broadly sensitized patients with nDSAs against Class I and II, nDSAs may be a risk marker for graft loss in the long term.

Published
2019

40. Antibodies against ARHGDIB are associated with long-term kidney graft loss

Author

Kamburova, E.G., Gruijters, M.L., Kardol-Hoefnagel, T., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Melchers, R.C., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Bemelman, F.J., Otten, H.G., Kamburova, E.G., Gruijters, M.L., Kardol-Hoefnagel, T., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F.E. van, Zuilen, A.D. van, Verhaar, M.C., Bots, M.L., Drop, A., Plaisier, L., Melchers, R.C., Seelen, M.A., Sanders, J.S., Hepkema, B.G., Lambeck, A.J.A., Bungener, L.B., Roozendaal, C., Tilanus, M.G., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H., Ittersum, F.J. van, Nurmohamed, S.A., Lardy, N.M., Swelsen, W., Pant, K. van der, Weerd, N.C. van der, Berge, I.J. Ten, Hoitsma, A., Boog, P.J. van der, Fijter, J.W. de, Betjes, M.G., Heidt, S., Roelen, D.L., Claas, F.H., Bemelman, F.J., and Otten, H.G.

Abstract

Contains fulltext : 215571.pdf (publisher's version ) (Open Access), The clinical significance of non-HLA antibodies on renal allograft survival is a matter of debate, due to differences in reported results and lack of large-scale studies incorporating analysis of multiple non-HLA antibodies simultaneously. We developed a multiplex non-HLA antibody assay against 14 proteins highly expressed in the kidney. In this study, the presence of pretransplant non-HLA antibodies was correlated to renal allograft survival in a nationwide cohort of 4770 recipients transplanted between 1995 and 2006. Autoantibodies against Rho GDP-dissociation inhibitor 2 (ARHGDIB) were significantly associated with graft loss in recipients transplanted with a deceased-donor kidney (N = 3276) but not in recipients of a living-donor kidney (N = 1496). At 10 years after deceased-donor transplantation, recipients with anti-ARHGDIB antibodies (94/3276 = 2.9%) had a 13% lower death-censored covariate-adjusted graft survival compared to the anti-ARHGDIB-negative (3182/3276 = 97.1%) population (hazard ratio 1.82; 95% confidence interval, 1.32-2.53; P = .0003). These antibodies occur independently from donor-specific anti-HLA antibodies (DSA) or other non-HLA antibodies investigated. No significant relations with graft loss were found for the other 13 non-HLA antibodies. We suggest that pretransplant risk assessment can be improved by measuring anti-ARHGDIB antibodies in all patients awaiting deceased-donor transplantation.

Published
2019

41. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets

Author

Rijkers, M, Schmidt, D, Lu, N, Kramer, CSM, Heidt, S, Mulder, A, Porcelijn, L, Claas, FHJ, Leebeek, Frank, Jansen, Gerard, Jongerius, I, Zeerleder, SS, Vidarsson, G, Voorberg, J, Haas, M, Rijkers, M, Schmidt, D, Lu, N, Kramer, CSM, Heidt, S, Mulder, A, Porcelijn, L, Claas, FHJ, Leebeek, Frank, Jansen, Gerard, Jongerius, I, Zeerleder, SS, Vidarsson, G, Voorberg, J, and Haas, M

Published
2019

42. RiCRN1, a crinkler effector from the arbuscular mycorrhizal fungus rhizophagus irregularis, functions in arbuscule development

Author

Voß, S., Betz, R., Heidt, S., Corradi, N., and Requena, N.

Subjects
Life sciences, biology, plant symbioses, arbuscular mycorrhiza, ddc:570, arbuscule, fungi, lcsh:QR1-502, food and beverages, crinkler (CRN) proteins, lcsh:Microbiology, effectors
Abstract

Arbuscular mycorrhizal (AM) symbiosis is one of the most prominent and beneficial plant–microbe interactions that facilitates mineral nutrition and confers tolerance to biotic and abiotic stresses. AM fungi colonize the root cortex and develop specialized structures called arbuscules where the nutrient exchange takes place. Arbuscule development is a highly controlled and coordinated process requiring the involvement of many plant proteins recruited at that interface. In contrast, much less is known about the fungal proteins involved in this process. Here, we have identified an AM fungal effector that participates in this developmental step of the symbiosis. RiCRN1 is a crinkler (CRN) effector that belongs to a subfamily of secreted CRN proteins from R. irregularis. CRNs have been so far only functionally characterized in pathogenic microbes and shown to participate in processes controlling plant cell death and immunity. RiCRN1 accumulates during symbiosis establishment parallel to MtPT4, the gene coding for an arbuscule-specific phosphate transporter. Expression in Nicotiana benthamiana leaves and in Medicago truncatula roots suggest that RiCRN1 is not involved in cell death processes. RiCRN1 dimerizes and localizes to nuclear bodies, suggesting that, similar to other CRNs, it functions in the plant nucleus. Downregulation of RiCRN1 using host-induced gene silencing led to an impairment of the symbiosis in M. truncatula and to a reduction of MtPT4, while ectopic expression of RiCRN1, surprisingly, led to a drastic reduction in arbuscule size that correlated with a decrease not only in MtPT4 but also in MtBCP1, a marker for initial stages of arbuscule development. Altogether, our results suggest that a tightly regulated expression in time and space of RiCRN1 is critical for symbiosis progression and for the proper initiation of arbuscule development.

Published
2018
Full Text
View/download PDF

44. PIRCHE-II: A NOVEL TOOL TO IDENTIFY PERMISSIBLE HLA MISMATCHES IN KIDNEY TRANSPLANTATION

Author

Geneugelijk, K., Niemann, M., Drylewicz, J., Zuilen, A.D. van, Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Hack, C.E., Reekum, F.E. van, Verhaar, M., Kamburova, E.G., Bots, M.L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Vanderlocht, J., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H.L., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J.M. ten, Bemelman, F.D.J., Hoitsma, A., Boog, P.J.M. van der, Fijter, J.W. de, Betjes, M.G.H., Heidt, S., Roelen, D.L., Claas, F.H.J., Otten, H.G., and Spierings, E.

Published
2017

45. DIFFERENTIAL EFFECT OF DONOR-SPECIFIC HLA ANTIBODIES IN LIVING VERSUS DECEASED DONOR KIDNEY TRANSPLANTATION

Author

Kamburova, E.G., Wisse, B.W., Joosten, I., Allebes, W.A., Meer, A. van der, Hilbrands, L.B., Baas, M.C., Spierings, E., Hack, C.E., Reekum, F. van, Zuilen, A. van, Verhaar, M.C., Bots, M.L., Drop, A.C.A.D., Plaisier, L., Seelen, M.A.J., Sanders, J.S.F., Hepkema, B.G., Lambeck, A.J., Bungener, L.B., Roozendaal, C., Tilanus, M.G.J., Voorter, C.E.M., Wieten, L., Duijnhoven, E.M. van, Gelens, M., Christiaans, M.H.L., Ittersum, F.J. van, Nurmohamed, A., Lardy, N.M., Swelsen, W., Pant, K.A. van der, Weerd, N.C. van der, Berge, I.J.M. ten, Bemelman, F.J., Hoitsma, A., Boog, P.J.M. van der, Fijter, H. de, Betjes, M.G.H., Heidt, S., Roelen, D.L., Claas, F.H.J., and Otten, H.G.

Published
2017

46. Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets

Author

Heidt, S, primary, Vergunst, M, additional, Anholts, J D H, additional, Swings, G M J S, additional, Gielis, E M J, additional, Groeneweg, K E, additional, Witkamp, M J, additional, de Fijter, J W, additional, Reinders, M E J, additional, Roelen, D L, additional, Eikmans, M, additional, and Claas, F H J, additional

Published
2019
Full Text
View/download PDF

47. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author

Kamburova, E.G., primary, Wisse, B.W., additional, Joosten, I., additional, Allebes, W.A., additional, van der Meer, A., additional, Hilbrands, L.B., additional, Baas, M.C., additional, Spierings, E., additional, Hack, C.E., additional, van Reekum, F.E., additional, van Zuilen, A.D., additional, Verhaar, M.C., additional, Bots, M.L., additional, Drop, A.C.A.D., additional, Plaisier, L., additional, Seelen, M.A.J., additional, Sanders, J.S.F., additional, Hepkema, B.G., additional, Lambeck, A.J.A., additional, Bungener, L.B., additional, Roozendaal, C., additional, Tilanus, M.G.J., additional, Voorter, C.E., additional, Wieten, L., additional, van Duijnhoven, E.M., additional, Gelens, M., additional, Christiaans, M.H.L., additional, van Ittersum, F.J., additional, Nurmohamed, S.A., additional, Lardy, N.M., additional, Swelsen, W., additional, van der Pant, K.A., additional, van der Weerd, N.C., additional, ten Berge, I.J.M., additional, Bemelman, F.J., additional, Hoitsma, A., additional, van der Boog, P.J.M., additional, de Fijter, J.W., additional, Betjes, M.G.H., additional, Heidt, S., additional, Roelen, D.L., additional, Claas, F.H., additional, and Otten, H.G., additional

Published
2018
Full Text
View/download PDF

49. Women with a history of recurrent miscarriage have a genetic predisposition to the HLA-G 3′UTR 14-bp insertion allele but increased HLA-G expression in their term placenta

Author

Eikmans, M., primary, Craenmehr, M.H.C., additional, Nederlof, I., additional, Cao, M., additional, Stegehuis-Kamp, J.A., additional, Anholts, J. D.H., additional, Drabbels, J.J.M., additional, Kapsenberg, H.M., additional, Claas, F.H.J., additional, and Heidt, S., additional

Published
2018
Full Text
View/download PDF

50. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author

Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results